Axial Therapeutics focuses on developing novel treatments for neurological diseases and disorders through the gut microbiome. They hope to improve the lives of patients with autism spectrum disorders and Parkinson’s disease through their microbial inspired therapeutics. Their science is based off research by co-founder Dr. Sarkis Mazmanian, who has done ground-breaking work, establishing key concepts surrounding the role of the gut-brain axis in neurodevelopmental disorders and neurodegenerative diseases. Axial Therapeutics’ platform is identifying new therapeutic targets and providing small molecule therapies that target the gut with minimal systemic absorption.

Axial Therapeutics

Drug notes:

About:

Jobs: